Updated results on AVO therapeutic triplet regimen in untreated patients with CLL
In this MEDtalk, MD Christine Ryan presents updated results from a multicenter phase 2 study investigating the effects of acalabrutinib, venetoclax, and obinutuzumab (AVO) combination in patients with previously untreated CLL. The study suggests AVO as a highly active triplet combination for this group of patients, also the once enriched for high-risk disease. AVO is currently undergoing investigation in a phase 3 study as well.
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.